A small change can make a big difference: a lesson from evolocumab
Background Evolocumab is an expensive proprotein convertase subtilisin/kexin type 9
(PCSK9) inhibitor which has been shown to significantly improve cardiovascular outcomes …
(PCSK9) inhibitor which has been shown to significantly improve cardiovascular outcomes …
[HTML][HTML] Proprotein convertase subtilisin/kexin type 9 inhibition: the big step forward in lipid control
R Rikhi, MD Shapiro - European Cardiology Review, 2023 - ncbi.nlm.nih.gov
The breakthrough discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) 20
years ago revolutionised the current understanding of cholesterol homeostasis. Genetic …
years ago revolutionised the current understanding of cholesterol homeostasis. Genetic …
Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors
D Leong, PE Wu - CMAJ, 2019 - Can Med Assoc
Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors Page 1 E894 CMAJ | AUGUST
12, 2019 | VOLUME 191 | ISSUE 32 © 2019 Joule Inc. or its licensors 1 Proprotein convertase …
12, 2019 | VOLUME 191 | ISSUE 32 © 2019 Joule Inc. or its licensors 1 Proprotein convertase …
[HTML][HTML] PCSK9 inhibitors revisited: effectiveness and safety of PCSK9 inhibitors in a real-life Spanish cohort
J Vicente-Valor, X García-González… - Biomedicine & …, 2022 - Elsevier
Introduction Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) have emerged
as a therapeutic option for patients with hypercholesterolemia who do not attain low-density …
as a therapeutic option for patients with hypercholesterolemia who do not attain low-density …
Pro‐protein subtilisin kexin‐9 (PCSK 9) inhibition in practice: lipid clinic experience in 2 contrasting UK centres
M Kohli, K Patel, Z MacMahon… - … journal of clinical …, 2017 - Wiley Online Library
Background Prescribing criteria have been suggested for proprotein convertase subtilisin
kexin‐9 (PCSK‐9) inhibitors but few studies exist of their real‐world effectiveness. Methods …
kexin‐9 (PCSK‐9) inhibitors but few studies exist of their real‐world effectiveness. Methods …
Real-world analyses of the treatment conditions in patients initiating proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor in Taiwan
Aims: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor is a powerful low
density lipoprotein cholesterol (LDL-C)-lowering therapy, but this drug is expensive. This …
density lipoprotein cholesterol (LDL-C)-lowering therapy, but this drug is expensive. This …
Proprotein Convertase Subtilisin Kexin-9 Inhibitors (PCSK9i) in Atherosclerotic Cardiovascular Disease: Real-World Data Welcome
The discovery of proprotein convertase subtilisin kexin-9 inhibitors (PCSK9i) epitomizes the
creative potential of modern translational research. 1 Approximately 20 years ago, scientists …
creative potential of modern translational research. 1 Approximately 20 years ago, scientists …
Randomized, partial blind study of the pharmacodynamics, pharmacokinetics and safety of multiple subcutaneous doses of alirocumab, a fully human monoclonal …
J Rey, F Poitiers, T Paehler, A Brunet… - Journal of the American …, 2014 - jacc.org
Background Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) monoclonal antibodies
such as alirocumab undergo target mediated clearance by binding PCSK9. Statins are …
such as alirocumab undergo target mediated clearance by binding PCSK9. Statins are …
[HTML][HTML] Proprotein convertase subtilisin/kexin type 9 inhibition in cardiovascular disease: current status and future perspectives
KH Cho, YJ Hong - The Korean Journal of Internal Medicine, 2020 - ncbi.nlm.nih.gov
Proprotein convertase subtilisin/kexin type 9 (PCSK9) targets the degradation of low-density
lipoprotein (LDL) receptors; it has been proved that its inhibition improves cardiovascular …
lipoprotein (LDL) receptors; it has been proved that its inhibition improves cardiovascular …
Adoption of PCSK9 inhibitors among patients with atherosclerotic disease
EJ Dayoub, LA Eberly, AS Nathan… - Journal of the …, 2021 - Am Heart Assoc
Background PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors represent a
promising class of lipid‐lowering therapy, although their use has been limited by cost …
promising class of lipid‐lowering therapy, although their use has been limited by cost …